Evidence map›Paper›PMID 31262666›Full record

ArticleClinical lymphoma, myeloma & leukemia2019

Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Matthew Austin, Peter J Quesenberry, Corey E Ventetuolo, Olin Liang, John L Reagan

Open access · greenAbstract read
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Hematopoietic stem cells and extramedullary hematopoiesis in the lungs.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023
    Review
  4. Pulmonary Hypertension: A Contemporary Review.American journal of respiratory and critical care medicine · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Matthew AustinDivision of Hematology and Oncology, Yale University School of Medicine, New Haven, CT.
Peter J QuesenberryDivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
Corey E VentetuoloDivision of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
Olin LiangDivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
John L ReaganDivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI. Electronic address: john_reagan@brown.edu.
Brown University · USRhode Island Hospital · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Stem Cells and AgingP20GM119943 · NIGMS · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2017 to 2021
$10.6M
TRANSFUSION BIOLOGY AND MEDICINET32HL066987 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI JOHN P MANIS · 2001 to 2026
$10.2M
Endothelial Plasticity in Human DiseaseR01HL112860 · NHLBI · RHODE ISLAND HOSPITAL · PI LIANG, OLIN D. · 2012 to 2017
$2.0M
The Role of NPR-C In Modulation Of Acute Lung InjuryR01HL123965 · NHLBI · RHODE ISLAND HOSPITAL · PI HARRINGTON, ELIZABETH O, KLINGER, JAMES RAYMOND · 2015 to 2018
$1.2M
Basic Aspects of Hematopoietic Stem Cells and AgingR01DK112808 · NIDDK · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2017 to 2019
$869k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL112860NHLBI NIH HHS R01 HL123965NHLBI NIH HHS T32 HL066987NIDDK NIH HHS R01 DK112808NIGMS NIH HHS P20 GM119943
6 · The paper itself

Abstract

backgroundMyelofibrosis (MF), a rare disorder characterized by bone marrow fibrosis, has been implicated as a cause of pulmonary hypertension (PH). To date, studies examining this association have not looked at the impact of PH on survival in MF. We examined the relationship between MF and PH by echocardiogram (echo) using a retrospective patient database and examined the influence of PH on overall survival. PATIENTS AND

methodsIn this single-center retrospective chart review, we identified 65 patients with biopsy-proven primary and secondary MF, 31 of whom underwent transthoracic echo. After accounting for chronic obstructive pulmonary disease and left-sided or valvular heart dysfunction, which excluded 6 patients, we identified 14 patients (56%) who had echo evidence of group 5 PH (ie, PH due to unclear or multifactorial mechanisms), 8 with primary MF and 6 with secondary MF. MF patients with PH trended toward being predominantly female, being older, and less often having constitutional symptoms compared to the non-PH cohort.

resultsThere was no effect of the presence of PH on overall survival in the entire MF cohort or in any subgroup analyzed, including primary MF versus secondary MF and primary MF intermediate risk patients.

conclusionGiven the high prevalence of MF-associated PH, there may be a larger role for routine echo screening in MF patients. Further, the underlying association between PH and MF may signify an endothelial plasticity or increased telomerase activity as part of the pathogenesis of MF.

Indexed as

AgedAged, 80 and overBiomarkersBiopsyEchocardiographyEpithelial-Mesenchymal TransitionFemaleHumansHypertension, PulmonaryMaleMiddle AgedPrevalencePrimary MyelofibrosisPrognosisRetrospective StudiesSurvival AnalysisBiomarkersEchocardiographyEndothelial–mesenchymal transitionOverall survivalPrevalenceTelomerase

Identifiers

PMID31262666
PMCPMC6814397
OpenAlexW2945812716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.